Relationship between selected microRNAs, pentraxin 3 and uromodulin in pathophysiology of septic acute kidney injury
9 affiliations
- 1Department of Internal Medicine and Cardiology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
- 2Department of Internal medicine III – Nephrology, Endocrinology and Rheumatology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- 3Department of Internal medicine III – Nephrology, Endocrinology and Rheumatology, University Hospital Olomouc, Olomouc, Czech Republic
- 4Department of Anesthesiology and Intensive Care, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
- 5BioVendor – Laboratorni medicina s.r.o, Brno, Czech Republic
- 6Institute of Laboratory Medicine, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
- 7Lab4Life Ostrava FNOU, Ostrava, Czech Republic
- 8Department of Anesthesiology and Intensive Care, University Hospital Olomouc, Olomouc, Czech Republic
- 9Blood Center, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
Abstract
Background: Acute kidney injury (AKI) is a common complication of sepsis and is associated with increased morbidity and mortality in critically ill patients. Combined assessment of serum pentraxin 3 (PTX3), uromodulin (UMOD), and circulating microRNAs (miRNAs) may improve understanding of the pathophysiology of septic AKI.
Methods: In this study, 81 critically ill adults with sepsis were stratified into AKI and non-AKI groups, and 90 healthy volunteers served as controls. Blood samples were collected on days 1 and 4 after the diagnosis of sepsis. PTX3 and UMOD concentrations were measured by ELISA, and miRNA expression was assessed by RT-qPCR. Seven miRNAs were validated, and their target genes associations were analyzed using TargetScanHuman8.0.
Results: PTX3 and UMOD distinguished healthy controls from septic patients, whereas only PTX3 differentiated patients with AKI from non-AKI. Baseline PTX3 and procalcitonin were independently associated with AKI on days 1 and 4. In AKI group, four analyzed miRNAs showed significant intercorrelations on day 1; however, these weakened by day 4 with changes in renal function and sepsis. Selected miRNAs were interpreted in the context of predicted target genes and pathways related to NF-κB signaling, renal cell apoptosis, and autophagy/mitophagy, rather than as direct causal regulators demonstrated in this study.
Conclusions: PTX3, UMOD, and selected miRNAs provide complementary information on septic AKI and support a multifactorial concept of its pathophysiology.
The study was registered at ClinicalTrials.gov (ID: NCT06498336) on May 2, 2024 to March 31, 2026.
Related
- Exploratory Analysis of Selected MicroRNAs as Tissue-Based Candidate Biomarkers in Ovarian Cancer
- MicroRNAs in Neurodevelopment and Their Relationship with Neurological, Neuropsychiatric and Neurodegenerative Diseases
- Evaluation of Serum Pentraxin-3 and Heavy Metal Levels in Patients with Acute Coronary Syndrome
- Targeting neuronal pentraxin 1 microRNA-492 exerts pro-tumorigenic effects in colorectal cancer through stimulation of proliferation, migration, and invasion
- Case Report: Uromodulin-associated autosomal dominant tubulointerstitial kidney disease: case analysis and literature review
BibTeX
@article{petejova2026relationship,
title = {{Relationship between selected microRNAs, pentraxin 3 and uromodulin in pathophysiology of septic acute kidney injury}},
author = {Nadezda Petejova and Arnost Martinek and Josef Zadrazil and Pavel Horak and Peter Sklienka and Marcela Kanova and Iveta Krepelkova and Radka Sigutova and Martin Drapela and Olga Klementova and Paula Dzurnakova and Vladimir Hrabovsky and Katerina Matejova and Zuzana Cermakova and David Stejskal},
journal = {Renal Failure},
year = {2026},
month = nov,
doi = {10.1080/0886022x.2026.2754639},
url = {https://doi.org/10.1080/0886022x.2026.2754639},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Relationship between selected microRNAs, pentraxin 3 and uromodulin in pathophysiology of septic acute kidney injury
AU - Nadezda Petejova
AU - Arnost Martinek
AU - Josef Zadrazil
AU - Pavel Horak
AU - Peter Sklienka
AU - Marcela Kanova
AU - Iveta Krepelkova
AU - Radka Sigutova
AU - Martin Drapela
AU - Olga Klementova
AU - Paula Dzurnakova
AU - Vladimir Hrabovsky
AU - Katerina Matejova
AU - Zuzana Cermakova
AU - David Stejskal
PY - 2026
DA - 2026/11/09
JO - Renal Failure
DO - 10.1080/0886022x.2026.2754639
UR - https://doi.org/10.1080/0886022x.2026.2754639
AB - Background: Acute kidney injury (AKI) is a common complication of sepsis and is associated with increased morbidity and mortality in critically ill patients. Combined assessment of serum pentraxin 3 (PTX3), uromodulin (UMOD), and circulating microRNAs (miRNAs) may improve understanding of the pathophysiology of septic AKI. Methods: In this study, 81 critically ill adults with sepsis were stratified into AKI and non-AKI groups, and 90 healthy volunteers served as controls. Blood samples were collected on days 1 and 4 after the diagnosis of sepsis. PTX3 and UMOD concentrations were measured by ELISA, and miRNA expression was assessed by RT-qPCR. Seven miRNAs were validated, and their target genes associations were analyzed using TargetScanHuman8.0. Results: PTX3 and UMOD distinguished healthy controls from septic patients, whereas only PTX3 differentiated patients with AKI from non-AKI. Baseline PTX3 and procalcitonin were independently associated with AKI on days 1 and 4. In AKI group, four analyzed miRNAs showed significant intercorrelations on day 1; however, these weakened by day 4 with changes in renal function and sepsis. Selected miRNAs were interpreted in the context of predicted target genes and pathways related to NF-κB signaling, renal cell apoptosis, and autophagy/mitophagy, rather than as direct causal regulators demonstrated in this study. Conclusions: PTX3, UMOD, and selected miRNAs provide complementary information on septic AKI and support a multifactorial concept of its pathophysiology. The study was registered at ClinicalTrials.gov (ID: NCT06498336) on May 2, 2024 to March 31, 2026.
SN - 0886-022X
SN - 1525-6049
ER -